Author of

• 17556

  +

  P2.03a - Poster Session with Presenters Present (ID 464)

  • Event: WCLC 2016
  • Type: Poster Presenters Present
  • Track: Advanced NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)

  • 17593

    +

    P2.03a-037 - Prognosis of Advanced Non-Small Cell Lung Cancer (NSCLC) Refractory to First-Line Platinum Chemotherapy (ID 5320)

    14:30 - 14:30  |  Author(s): Y.S. Kim
    • Abstract

    Background:
    Platinum based chemotherapy is a standard treatment for patients with advanced non-small cell lung cancer (NSCLC) without EGFR mutation or ALK translocation. However, some patients show no response to 1st line treatment. In this study we investigated characteristics and treatment outcome of salvage treatment in these population of advanced NSCLC primary refractory to 1st line chemotherapy including platinum.
    
    Methods:
    We investigated consecutive patients with NSCLC stage IIIB-IV who received platinum-doublet chemoherapy as a first line treatment between 2014-2015 in a single center. Primary refractory NSCLC was defined as progressive disease(PD) according to RECIST criteria at the first evaluation. Survival was estimated by Kaplan-meier method.
    
    Results:
    Among 102 patients without known EGFR mutation or ALK translocation who received platinum doublet as 1st line, 13 patients (12.7%) showed PD on the first evaluation of tumor response. Median age was 68 years (range 30 -84 years). Five patients had adenocarcinoma, one squamous cell carcinoma, one sarcomatoid carcinoma, and the other five had other histology. First chemotherapy regimen included pemetrexed (n=6), gemcitabine (n=6), and paclitaxel (n=1). Eight of 13 patients received subsequent salvage chemotherapy (gemcitabine based in four, taxane based in three, etoposide+ifosfamide+cisplatin in one) and no one had objective response. Three patients had stable disease, one patient showed PD to subsequent chemotherapy, and response could not be evaluated in the other four patients. Median overall survival of the 13 patients was 3.2 months (95% confidence interval 2.3 - 4.1 months).
    
    Conclusion:
    NSCLC which is primarily refractory to 1st line platinum based chemotherapy had poor survival. The efficacy of other cytotoxic chemotherapy regimen as a salvage treatment was limited. Studies to find an optimal salvage treatment strategy in this population are needed.